NanoVibronix CEO Brian Murphy Provides Business Update in Letter to Shareholders - Seite 2

Additionally, we recently announced our first contractual agreement in the Workers’ Compensation arena.  Our product is a great adjunct to the services provided in this market, and we intend to pursue additional agreements of this nature.

Covid-19 has limited our ability to present our technologies in person as many professional exhibitions have been cancelled or became virtual. We continue to look for opportunities to present and look forward to onsite participation at expos and trade conferences as soon as those opportunities are available. 

Demand for our products continues to strengthen, which we believe will soon be reflected in our financial results.

Supply Chain

Like most business, supply chain constraints are currently a challenge for our business, but we are identifying alternative and parllel sources for componentry, with the additional benefit of improved economics sourcing. In addition to component alternatives, we are also exploring contract manufacturing opportunities. While we ended the third quarter with a backlog of orders, we expect to be current with fulfillments by the end of Q4.

We have committed to a Q1 2022 delivery of a more significant quantity than ever before. 

Product Validation Research

The success of medical devices is reliant upon strong clinical evidence, and we have been active in this area. Following the succesful independent study published earlier this year, we are completing an additional clinical study in the United Kingdom on UroShield which we expect to be published next year. Additionally, we recently released the final results of a randomized control trial using PainShield to treat the pain and physical limitations of Tennis Elbow (Lateral Epicondylitis).  The  tennis elbow study achieved exceptional results using  PainShield,reporting an incredible 92% effectiveness in resolving the pain associated with Lateral Epicondylitis, solid proof of an effective clinical application.

The UroShield is currently approved for sale in the United States, Europe, Australasia and India  and has been shown to prevent Catheter Associated Urinary Tract Infection (CAUTI).  The PainShield is currently approved for sale in the United States, Europe, Australasia and India, and is intended to treat and resolve pain through the application of our proprietary, patented, Surface Acoustic Wave (SAW) technology.  We continue to actively seek oppertunities to conduct further research and hope to be able to update shortly.